Earnings call transcript: Legend Biotech’s Q1 2026 earnings miss forecasts

Legend Biotech reported Q1 2026 EPS of -$0.15 versus consensus of $0.01, while revenue of $305.1 million slightly missed the $305.88 million forecast. Gross margin fell to 41% from 57% due to one-time manufacturing ramp costs, though management expects margins to recover above 50% in Q2 and reaffirmed 2026 adjusted profitability. Shares fell 3.95% premarket to $24.75 after the miss, partially offset by strong CARVYKTI sales growth and upbeat full-year guidance.

Analysis

The quarter reads like a classic quality-vs-timing setup: the core asset is still compounding, but the market is being forced to underwrite near-term noise from manufacturing scale-up and a temporarily distorted margin profile. That typically creates the best entry points in platform biotech, because the pain is visible immediately while the operating leverage shows up with a lag of 1-2 quarters. The key second-order point is that a durable recovery in gross margin above 50% would not just lift EPS; it would materially expand the internal capital budget for the earlier-stage pipeline, reducing external financing risk and making the in vivo platform worth more as an option.

Competitive dynamics remain favorable despite the headline miss. If the commercial mix continues shifting toward earlier lines and community sites, the business becomes harder to displace because treatment-center activation creates a sticky referral network; that is more defensible than a pure label-based advantage. The more interesting read-through is to JNJ: near-term volatility in LEGN likely has little bearing on CARVYKTI’s long runway, but it may slow the multiple expansion of the broader cell-therapy complex until investors see proof that earlier-line adoption and manufacturing economics can coexist.

The main tail risk is not demand; it’s execution drift. If the gross margin bounce in the next quarter fails to materialize, the market will likely reprice the story from ‘temporary hiccup’ to ‘structural complexity,’ and the stock could retest the low-$20s quickly. Conversely, any mid-year clinical readout from the in vivo program with clean safety plus even modest efficacy would give the equity a second catalyst stack, because the market is currently paying almost nothing for that platform optionality.

Consensus appears too focused on the earnings miss and not enough on the fact that management is signaling a near-term inflection in both margins and mix. That means the downside from here is probably more about timing than thesis failure. In our view, this is a better buy-the-dip than sell-the-rally name, but only if one can tolerate a 1-2 quarter proving period.

Key Decisions for Investors

• Initiate a tactical long in LEGN over the next 3-5 trading days if the stock holds above the post-earnings low; target a 10-15% rebound on confirmation of Q2 margin recovery, with a stop if management reiterates but does not evidence >50% gross margin in the next print.
• Buy LEGN Aug/Oct upside calls as a catalyst trade into the expected mid-year in vivo data readout; structure for asymmetric upside because the market is currently assigning low value to pipeline optionality.
• Pair trade: long LEGN / short XBI for 4-8 weeks, betting idiosyncratic margin normalization and commercial momentum outperform the broader biotech basket if risk appetite stays mixed.
• For existing longs in JNJ, hedge with a modest short LEGN or call spread sale only if you want to isolate cell-therapy read-through risk; the fundamental exposure is more to sentiment than earnings.
• If LEGN fails to reclaim the pre-earnings gap within 2-3 weeks, reduce exposure: that would signal the market is demanding proof rather than trusting guidance, and the trade becomes range-bound rather than re-rating.